{"id":"cadonilimab-combined-tpc-chemotherapy","safety":{"commonSideEffects":[{"rate":"20-30%","effect":"Fatigue"},{"rate":"15-25%","effect":"Diarrhea"},{"rate":"10-20%","effect":"Nausea"},{"rate":"5-15%","effect":"Vomiting"},{"rate":"5-10%","effect":"Rash"},{"rate":"5-10%","effect":"Pyrexia"},{"rate":"5-10%","effect":"Cough"},{"rate":"5-10%","effect":"Dyspnea"},{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Muscle pain"}]},"_chembl":{"chemblId":"CHEMBL4594456","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By binding to PD-1, cadonilimab prevents its interaction with PD-L1, allowing T cells to recognize and attack cancer cells. This mechanism is thought to be responsible for the therapeutic effects of cadonilimab in combination with TPC chemotherapy.","oneSentence":"Cadonilimab is a monoclonal antibody that targets the PD-1 receptor, thereby inhibiting the PD-1/PD-L1 pathway and enhancing anti-tumor immune response.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:41:58.340Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic non-small cell lung cancer, PD-L1 positive"},{"name":"Metastatic triple-negative breast cancer"}]},"trialDetails":[{"nctId":"NCT06889610","phase":"PHASE2","title":"A Phase II Clinical Study of Multimodal Ablation Combined With Systemic Drug Therapy for Advanced Solid Tumors.","status":"RECRUITING","sponsor":"Fudan University","startDate":"2025-11-04","conditions":"Triple Negative Breast Cancer Metastatic, Melanoma Metastatic, Colorectal Cancer Metastatic","enrollment":95},{"nctId":"NCT06664983","phase":"PHASE3","title":"TPC Combined With Cadonilimab VS. TPC Alone in Anti-PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-10-21","conditions":"Nasopharyngeal Cancinoma (NPC)","enrollment":84}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["cadonilimab combined NAB-paclitaxel, cisplatin, and capecitabine"],"phase":"phase_3","status":"active","brandName":"cadonilimab combined TPC chemotherapy","genericName":"cadonilimab combined TPC chemotherapy","companyName":"Sun Yat-sen University","companyId":"sun-yat-sen-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Cadonilimab is a monoclonal antibody that targets the PD-1 receptor, thereby inhibiting the PD-1/PD-L1 pathway and enhancing anti-tumor immune response. Used for Metastatic non-small cell lung cancer, PD-L1 positive, Metastatic triple-negative breast cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}